Nov 10, 2022 · In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment.

Dec 16, 2022 · While overdiagnosis is a concern for most thyroid cancers, the authors also report elevated GLP-1 RA–associated risk of the more aggressive types of thyroid cancer—medullary tumors, which arise from parafollicular cells.

Glucagon-like peptide 1 (GLP-1) recep-tor agonists can be safely used in all patients with thyroid cancers that are derived from the thyroid follicular epithelium (papillary and follicular thyroid cancer).

Jan 23, 2025 · Several studies 10-14 have proposed a potential biological association between GLP-1RA and the development of medullary thyroid cancer in rodents. Furthermore, GLP-1 receptors have been found on papillary thyroid cancer cells, 15-18 raising concern for the potential impact of GLP-1RA therapy on this more common cause of thyroid cancer.

Apr 10, 2024 · GLP1 receptor agonist use was not associated with increased risk of thyroid cancer (hazard ratio 0.93, 95% confidence interval 0.66 to 1.31; rate difference −0.13, 95% confidence interval −0.61 to 0.36 events per 10 000 person years). The hazard ratio for medullary thyroid cancer was 1.19 (0.37 to 3.86).

The study delved into the molecular mechanisms underlying thyroid diseases induced by GLP-1 analogs, using thyroid cancer cell lines that express GLP-1R. In contrast to previous rodent studies, the results indicated that GLP-1R activation inhibited the proliferation and migration of human thyroid cancer cells.

Jan 14, 2025 · FOR IMMEDIATE RELEASE FROM MARY ANN LIEBERT, INC., PUBLISHERS. New Rochelle, NY, January 8, 2025—A new study found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer.The study is published in the peer-reviewed journal Thyroid ®, the official journal of the American Thyroid Association ® sup> (ATA ®).

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer.

Compared with placebo or other interventions, GLP-1 receptor agonists’ use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60).

Jan 8, 2025 · In an intention-to-treat analysis, the use of GLP-1RA was not associated with an increased risk of thyroid cancer compared with DPP-4i (adjusted HR: 0.81 [CI: 0.59–1.12]), and no trend was observed with increasing cumulative doses of GLP-1RA.